Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in its stock price, attributed to alleged violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit was filed by Bleichmar Fonti & Auld LLP on behalf of investors, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 2, 2026, to request to lead the case in the U.S. District Court for the District of Maryland [4]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [7]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [7]. Group 3: Stock Price Impact - Following the announcement of poor financial results on September 25, 2025, CarMax's stock price fell by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [8]. - The unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 outlook, led to an additional stock price drop of over 24% [8]. Group 4: Company Operations - CarMax's management had previously emphasized strong demand for its vehicles, which was later alleged to have been artificially boosted by pre-tariff purchases [5]. - The law firm is also investigating whether CarMax adequately assessed its portfolio of car loans following the CEO's departure [6].

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][4][6]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses and differentiation from competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].

Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include those who purchased or acquired CarMax securities between June 20, 2025, and November 5, 2025 [1] Allegations Against Defendants - The complaint alleges that during the class period, defendants made false and misleading statements, overstating CarMax's growth prospects, which were actually inflated due to temporary factors related to customer behavior influenced by tariff speculation [2] - It is claimed that the positive statements made by defendants regarding the company's business and operations were materially misleading and lacked a reasonable basis [2] Lead Plaintiff Process - CarMax investors have until January 2, 2026, to seek appointment as a lead plaintiff representative of the class, or they may choose to remain absent class members [3] - The lead plaintiff will act on behalf of all class members and select counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3] Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of fraud and corporate misconduct [4]

Core Viewpoint - A securities class action lawsuit has been filed against StubHub Holdings, Inc. for allegedly making false and misleading statements in its Offering Documents related to its September 2025 initial public offering [1][2]. Group 1: Allegations Against StubHub - The lawsuit claims that StubHub failed to disclose significant changes in the timing of payments to vendors, which adversely affected its free cash flow [2]. - It is alleged that these undisclosed changes rendered StubHub's free cash flow reports materially misleading [2]. - The complaint asserts that the positive statements made by StubHub regarding its business operations and prospects were materially false and lacked a reasonable basis due to the undisclosed issues [2]. Group 2: Legal Process for Investors - StubHub investors have until January 23, 2026, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. - Investors can choose to participate actively or remain absent from the class without affecting their ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected StubHub investors to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its G6 and G7 continuous glucose monitoring systems during the specified Class Period from January 8, 2024, to September 17, 2025 [1][2]. Allegations Against DexCom - The complaints allege that DexCom made unauthorized design changes to its G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The allegations suggest that these actions increased DexCom's exposure to regulatory scrutiny and potential legal, reputational, and financial harm [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, or they may choose to remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a revenue decline of 7.7% year-over-year in its Design IP segment, totaling $425.9 million, and a net income decline of 43% year-over-year, amounting to $242.5 million [6]. Group 3: Market Reaction - Following the Q3 2025 financial results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share, a drop of $217.59 per share [6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride admitted to issues with customer experience, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 2025 outlook, led to an additional stock drop of over 24% [6]. Group 3: Company Background - CarMax is a leading retailer of used cars, emphasizing a seamless customer experience and strong demand for its vehicles [3]. - The firm Bleichmar Fonti & Auld LLP, known for representing plaintiffs in securities class actions, is handling the lawsuit against CarMax [10].

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Freeport, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/freeport-mcmoran-inc-clas ...